RLAY Stock Price, Relay Therapeutics Inc Quote, Chart

Market Summary

USD6.36-0.06

Market Closed

-0.93%

RLAY Alerts

Big jump in Revenue (Y/Y)

Losses in recent quarter

RLAY Stock Price

View Fullscreen

RLAY RSI Chart

RLAY Valuation

Market Cap

844.2M

Price/Earnings (Trailing)

-2.57

Price/Sales (Trailing)

17.49

Price/Free Cashflow

-2.94

RLAY Price/Sales (Trailing)

RLAY Profitability

Return on Equity

-44.13%

Return on Assets

-39.11%

Free Cashflow Yield

-34.05%

RLAY Fundamentals

RLAY Revenue

Revenue (TTM)

48.3M

Rev. Growth (Yr)

44.17%

Rev. Growth (Qtr)

82.01%

RLAY Earnings

Earnings (TTM)

-329.1M

Earnings Growth (Yr)

13.64%

Earnings Growth (Qtr)

2.52%

Breaking Down RLAY Revenue

Last 7 days

-5.6%

Last 30 days

-9.5%

Last 90 days

-35.7%

Trailing 12 Months

-38.2%

How does RLAY drawdown profile look like?

RLAY Financial Health

Current Ratio

20.73

RLAY Investor Care

Shares Dilution (1Y)

9.15%

Diluted EPS (TTM)

-2.64

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	48.3M	0	0	0
2023	21.6M	34.5M	47.4M	45.2M
2022	2.0M	2.1M	5.5M	8.8M
2021	62.2M	41.7M	21.3M	830.0K
2020	0	7.2M	5.3M	82.7M
2019	0	0	0	0

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Relay Therapeutics Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Apr 29, 2024	catinazzo thomas	sold	-10,814	6.38	-1,695	chief financial officer
Apr 29, 2024	rahmer peter	sold	-8,581	6.38	-1,345	see remarks
Apr 29, 2024	bergstrom donald a	sold	-17,136	6.38	-2,686	president, r&d
Apr 29, 2024	adams brian	sold	-10,354	6.38	-1,623	chief legal officer
Mar 27, 2024	adams brian	sold	-2,679	7.7	-348	chief legal officer
Mar 27, 2024	bergstrom donald a	sold	-5,890	7.7	-765	president, r&d
Mar 27, 2024	rahmer peter	sold	-2,294	7.7	-298	see remarks
Mar 27, 2024	catinazzo thomas	sold	-2,679	7.7	-348	chief financial officer
Jan 29, 2024	catinazzo thomas	sold	-19,328	9.64	-2,005	chief financial officer
Jan 29, 2024	adams brian	sold	-18,595	9.64	-1,929	chief legal officer

Which funds bought or sold RLAY recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 13, 2024	BOSTON FAMILY OFFICE LLC	unchanged	-	-33,000	103,000	0.01%
May 13, 2024	UBS Group AG	added	54.55	338,634	2,389,790	-%
May 13, 2024	Jump Financial, LLC	new	-	85,623	85,623	-%
May 13, 2024	FOX RUN MANAGEMENT, L.L.C.	added	116	84,822	219,045	0.05%
May 13, 2024	E Fund Management Co., Ltd.	added	25.41	-10,502	182,019	0.01%
May 13, 2024	Handelsbanken Fonder AB	added	32.88	-	325,000	-%
May 13, 2024	XTX Topco Ltd	added	228	179,677	301,547	0.04%
May 13, 2024	RENAISSANCE TECHNOLOGIES LLC	added	135	2,771,000	6,335,000	0.01%
May 13, 2024	Balyasny Asset Management L.P.	new	-	8,297,000	8,297,000	0.01%
May 13, 2024	FIRST TRUST ADVISORS LP	new	-	984,745	984,745	-%

Are Funds Buying or Selling RLAY?

Are funds buying RLAY calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own RLAY

No. of Funds

Unveiling Relay Therapeutics Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 14, 2024	price t rowe associates inc /md/	7.0%	8,589,425	SC 13G
Feb 14, 2024	casdin capital, llc	5.99%	7,387,943	SC 13G/A
Feb 13, 2024	vanguard group inc	8.64%	10,650,387	SC 13G/A
Jan 26, 2024	blackrock inc.	7.8%	9,573,423	SC 13G/A
Jan 23, 2024	state street corp	3.98%	4,903,578	SC 13G/A
Oct 02, 2023	casdin capital, llc	5.16%	6,298,574	SC 13G
Jul 10, 2023	fmr llc	-	0	SC 13G/A
Feb 09, 2023	vanguard group inc	8.59%	10,384,218	SC 13G/A
Feb 09, 2023	fmr llc	-	0	SC 13G/A
Feb 03, 2023	state street corp	5.18%	6,264,497	SC 13G

Recent SEC filings of Relay Therapeutics Inc

View All Filings

Date Filed	Form Type	Document
May 02, 2024	10-Q	Quarterly Report
May 02, 2024	8-K	Current Report
Apr 29, 2024	4	Insider Trading
Apr 29, 2024	4	Insider Trading
Apr 29, 2024	4	Insider Trading
Apr 29, 2024	4	Insider Trading
Apr 23, 2024	ARS	ARS
Apr 23, 2024	DEF 14A	DEF 14A
Apr 23, 2024	DEFA14A	DEFA14A
Mar 29, 2024	4	Insider Trading

Peers (Alternatives to Relay Therapeutics Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	49.2B	6.8B	22.08%	-1.47%	-8.24	7.18	-64.45%	-224.75%
HILS	22.5B	216.3K	-0.77%	465779.94%	-2.5K	104.0K	-	-8.13%
ALNY	18.7B	2.0B	-0.34%	-28.23%	-56.37	9.34	75.20%	68.82%
BMRN	15.1B	2.5B	-13.63%	-16.32%	73.61	6.12	13.74%	186.89%
INCY	12.8B	3.8B	5.96%	-13.81%	17.19	3.4	8.58%	129.81%
MID-CAP
BBIO	5.4B	107.9M	8.09%	95.42%	-9.93	48.09	54.84%	-28.31%
APLS	5.0B	524.1M	-20.37%	-53.19%	-11.99	9.55	394.93%	39.61%
AXSM	3.7B	251.0M	11.93%	-0.48%	-12.4	14.64	73.58%	-86.73%
ARWR	2.8B	240.7M	-7.33%	-42.62%	-6.04	12.77	-1.03%	-213.43%
ACAD	2.5B	813.8M	-13.36%	-32.87%	-1.4K	3.01	56.43%	98.83%
SMALL-CAP
CPRX	1.9B	411.3M	8.34%	25.49%	29.91	4.73	60.38%	-34.49%
NVAX	1.9B	996.6M	214.95%	66.21%	-4.75	1.9	-26.66%	65.49%
CRBP	456.3M	881.7K	4.53%	306.67%	-13.52	481.06	-77.61%	33.36%
INO	297.2M	4.9M	3.99%	24.13%	-2.38	61.07	-54.97%	48.23%
IBIO	16.2M	2.1M	-6.93%	99.64%	-0.7	7.61	-13.45%	69.54%

Relay Therapeutics Inc News

Latest updates

Relay Therapeutics Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)																			(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q3	2019Q2
Revenue	82.0%	10.00	5.00	25.00	8.00	7.00	8.00	4.00	1.00	1.00	0.00	0.00	1.00	40.00	80.00	1.00	1.00	2.00	2.00	2.00
Operating Expenses	8.9%	100	92.00	99.00	106	101	73.00	86.00	78.00	63.00	68.00	62.00	194	43.00	48.00	37.00	28.00	26.00	22.00	20.00
S&GA Expenses	-100.0%	-	17.00	18.00	20.00	20.00	16.00	16.00	17.00	16.00	16.00	15.00	14.00	13.00	16.00	12.00	6.00	5.00	4.00	4.00
R&D Expenses	-	-	-	-	-	-	-	-	-	-	-	-	-	31.00	32.00	24.00	22.00	22.00	18.00	16.00
Net Income	2.5%	-81.39	-83.49	-65.73	-98.50	-94.24	-67.50	-84.17	-76.79	-62.05	-67.46	-60.83	-193	-42.18	35.00	-36.08	-26.72	-24.89	-19.67	-17.54
Net Income Margin	9.9%	-6.82*	-7.57*	-6.88*	-9.98*	-14.91*	-33.06*	-53.24*	-125.70*	-195.38*	-438.40*	-12.27*	-5.66*	-	-	-	-	-	-	-
Free Cashflow	41.7%	-52.10	-89.31	-75.99	-70.10	-69.04	-59.39	-68.24	-58.95	-51.97	-40.59	-54.93	-28.52	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																	(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2019Q4
Assets	-0.3%	841	844	907	962	1,038	1,100	1,169	889	950	1,008	672	714	771	800	752	348	393
Current Assets	0.0%	770	770	832	884	958	1,020	1,087	856	916	976	639	681	742	770	722	316	361
Cash Equivalents	8.2%	156	144	151	146	161	152	355	108	119	283	229	260	263	449	559	137	43.00
Net PPE	-9.4%	10.00	11.00	11.00	12.00	12.00	12.00	11.00	9.00	9.00	7.00	6.00	7.00	6.00	6.00	7.00	7.00	8.00
Liabilities	4.0%	96.00	92.00	129	152	154	150	169	110	108	111	101	96.00	39.00	37.00	38.00	36.00	36.00
Current Liabilities	22.7%	37.00	30.00	51.00	72.00	70.00	64.00	71.00	44.00	42.00	24.00	29.00	25.00	16.00	14.00	16.00	13.00	12.00
Shareholder's Equity	-0.8%	746	752	778	810	883	950	1,000	780	842	898	571	619	733	763	714	-	-
Retained Earnings	-5.9%	-1,481	-1,400	-1,300	-1,300	-1,200	-1,058	-991	-906	-830	-768	-700	-639	-446	-404	-439	-241	-189
Additional Paid-In Capital	3.5%	2,229	2,153	2,099	2,067	2,042	2,019	2,004	1,698	1,681	1,667	1,272	1,258	1,179	1,167	1,153	15.00	9.00
Shares Outstanding	3.8%	132	127	123	122	121	121	111	108	108	95.00	93.00	92.00	-	-	-	-	-
Float	-	-	-	-	1,500	-	-	-	1,800	-	-	-	2,264	-	-	-	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																				(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2
Cashflow From Operations	43.6%	-50,323	-89,188	-75,397	-68,601	-67,130	-57,079	-66,145	-57,093	-49,173	-39,707	-53,199	-28,140	46,640	-35,272	-24,039	-20,844	-22,334	-	-	-
Share Based Compensation	41.1%	27,188	19,267	21,835	23,411	21,518	13,817	13,719	15,147	13,455	10,218	12,418	16,147	9,671	14,544	11,929	4,032	1,455	-	1,248	1,086
Cashflow From Investing	-82.4%	10,531	59,678	71,365	51,277	75,314	-146,936	27,187	43,388	-112,384	-292,745	20,787	26,068	-233,621	-76,420	20,073	87,648	50,371	-	-	-
Cashflow From Financing	123.2%	48,922	21,918	9,458	2,080	1,297	1,166	285,865	1,996	883	384,012	902	1,121	2,055	56.00	426,195	-93.00	351	-	-	-

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

RLAY Income Statement

2024-03-31

Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Revenue:
License and other revenue	$ 10,007	$ 226
Revenue from Contract with Customer, Product and Service [Extensible Enumeration]	us-gaap:LicenseAndServiceMember	us-gaap:LicenseAndServiceMember
Total revenue	$ 10,007	$ 226
Operating expenses:
Research and development expenses	82,403	82,827
Change in fair value of contingent consideration liability	(1,832)	(1,003)
General and administrative expenses	19,799	19,579
Total operating expenses	100,370	101,403
Loss from operations	(90,363)	(101,177)
Other income:
Interest income	8,951	6,941
Other income (expense)	25	(3)
Total other income, net	8,976	6,938
Net loss	$ (81,387)	$ (94,239)
Net loss per share, basic	$ (0.62)	$ (0.78)
Net loss per share, diluted	$ (0.62)	$ (0.78)
Weighted average shares of common stock, basic	130,843,013	121,320,865
Weighted average shares of common stock, diluted	130,843,013	121,320,865
Other comprehensive (loss) income:
Unrealized holding (loss) gain	$ (962)	$ 4,618
Total other comprehensive (loss) income	(962)	4,618
Total comprehensive loss	$ (82,349)	$ (89,621)

RLAY Balance Sheet

2024-03-31

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 152,866	$ 143,736
Investments	596,742	606,350
Prepaid expenses	13,188	16,702
Other current assets	7,304	3,315
Total current assets	770,100	770,103
Property and equipment, net	9,875	10,901
Operating lease assets	56,459	57,969
Restricted cash	2,707	2,707
Intangible asset	2,300	2,300
Total assets	841,441	843,980
Current liabilities:
Accounts payable	7,973	9,211
Accrued expenses	22,362	14,890
Operating lease liabilities	5,147	4,964
Other current liabilities	1,662	1,204
Total current liabilities	37,144	30,269
Operating lease liabilities, net of current portion	47,159	48,502
Contingent consideration liability	11,374	13,206
Total liabilities	95,677	91,977
Commitments and contingencies (Note 9)
Stockholders' equity:
Common stock, $0.001 par value; 300,000,000 shares authorized as of March 31, 2024, and December 31, 2023; 132,300,851 and 127,462,409 shares issued and outstanding as of March 31, 2024 and December 31, 2023, respectively	132	127
Additional paid-in capital	2,228,759	2,152,654
Accumulated other comprehensive loss	(1,158)	(196)
Accumulated deficit	(1,481,969)	(1,400,582)
Total stockholders' equity	745,764	752,003
Total liabilities and stockholders' equity	$ 841,441	$ 843,980

About Relay Therapeutics Inc

Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company's lead product candidates include RLY-4008, an oral small molecule inhibitor of fibroblast growth factor receptor 2 (FGFR2), which is in a first-in-human clinical trial for patients with advanced or metastatic FGFR2-altered solid tumors; RLY-2608, a lead mutant-PI3Ka inhibitor program that targets phosphoinostide 3 kinase alpha; and GDC-1971, an oral small molecule inhibitor of protein tyrosine phosphatase Src homology region 2 domain-containing phosphatase-2 that is in Phase 1 trial in patients with advanced solid tumors. In addition, it has collaboration and license agreements with D. E. Shaw Research, LLC to research certain biological targets through the use of D. E. Shaw Research computational modeling capabilities focused on analysis of protein motion to develop and commercialize compounds and products directed to such targets; and Genentech, Inc. for the development and commercialization of GDC-1971. The company was formerly known as Allostery, Inc. and changed its name to Relay Therapeutics, Inc. in December 2015. Relay Therapeutics, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

CEO	Dr. Sanjiv K. Patel M.A., M.B.A., M.D., MBBS
WEBSITE	relaytx.com
INDUSTRY	Biotechnology
EMPLOYEES	345

Relay Therapeutics Inc Frequently Asked Questions

What is the ticker symbol for Relay Therapeutics Inc? What does RLAY stand for in stocks?

RLAY is the stock ticker symbol of Relay Therapeutics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Relay Therapeutics Inc (RLAY)?

As of Tue May 14 2024, market cap of Relay Therapeutics Inc is 844.24 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of RLAY stock?

You can check RLAY's fair value in chart for subscribers.

What is the fair value of RLAY stock?

You can check RLAY's fair value in chart for subscribers. The fair value of Relay Therapeutics Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Relay Therapeutics Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for RLAY so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Relay Therapeutics Inc a good stock to buy?

The fair value guage provides a quick view whether RLAY is over valued or under valued. Whether Relay Therapeutics Inc is cheap or expensive depends on the assumptions which impact Relay Therapeutics Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for RLAY.

What is Relay Therapeutics Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Tue May 14 2024, RLAY's PE ratio (Price to Earnings) is -2.57 and Price to Sales (PS) ratio is 17.49. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. RLAY PE ratio will change depending on the future growth rate expectations of investors.